NCT04793984

Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Marinomed Biotech AG · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The current study will investigate the tolerability and efficacy of inhaled Carragelose® versus saline in hospitalized COVID-19 patients. As SARS-CoV-2 replicates readily in the lung, it is planed to apply Carragelose® in an inhalative form. Hospitalized COVID-19 patients with respiratory symptoms will inhale Inhaleen for 5 days.

Detailed description

The tolerability and efficacy of inhaled Carragelose® will be investigated in a randomized, double blind, placebo-controlled trial in hospitalized COVID-19 patients. Patients will inhale Inhaleen or Placebo 3 times a day for 7 minutes for 5 days. The primary objective of the trial is to demonstrate that Inhaleen inhalation improves the clinical status of hospitalized COVID-19 patients on day 8 compared to placebo inhalation.

Conditions

• Covid19

Interventions

Type	Name	Description
DEVICE	Carragelose	inhalation 3 times a day
DEVICE	NaCl	inhalation 3 times a day

Timeline

• Start date: 2021-03-08
• Primary completion: 2022-07-30
• Completion: 2022-07-30
• First posted: 2021-03-11
• Last updated: 2022-08-29

Locations

1 site across 1 country: Austria